Tubulis Technologies

Tubulis Technologies

Pre-clinical
Munich, GermanyFounded 2019tubulis.com

Reimagining Antibody Drug Conjugates NEWS January 27 Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board January 21 Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications January 08 Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development 1 / 3 […]

Founded
2019
Focus
AntibodiesBiologics

About

Reimagining Antibody Drug Conjugates NEWS January 27 Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board January 21 Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications January 08 Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development 1 / 3 […]

Funding History

3

Total raised: $208.7M

Series B$138MEQT Life SciencesJan 15, 2024
Series A$60MAndera PartnersJun 15, 2022
Seed$10.7MHigh-Tech GründerfondsJan 15, 2020

Company Info

TypePrivate
Founded2019
LocationMunich, Germany
StagePre-clinical
SIMILAR COMPANIES
300Microns
300Microns
Pre-clinical · Munich
BetaSense
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Mireca Medicines
Pre-clinical · Munich
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile